Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT048 in Advanced CLDN18.2+ Solid Tumors
NCT05393986Phase 1Unknown
- Sponsor
- Peking University
- Start
- Aug 2022
- Primary completion
- Jun 2023
- Modality
- Autologous CAR-T
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT-048 in gastric adenocarcinoma, pancreatic cancer (PC) and gastroesophageal junction adenocarcinoma, sponsored by Peking University. Primary endpoints: Dose-limiting toxicity at 28 days and Maximum tolerated dose at 28 days. Status: unknown.
02
Drugs
CT-048
03
Conditions
gastric adenocarcinomapancreatic cancer (PC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05393986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05393986.